Eli Lilly's Revenue Soars While Analysts Keep It Cool

Yo, peep this: Eli Lilly just dropped a 47.67% revenue boost from Mounjaro sales, sendin’ their stocks flyin’ high, g. Wall Street’s keepin’ it cool with a 4% upside prediction, but competition’s lurkin’ like a shadow, especially Novo Nordisk. Investors are holdin’ tight, hopin’ for a blockbuster ride in the next year and a half, as hurdles pop up like whack-a-mole.